SEARCH

SEARCH BY CITATION

References

  • Block M. L., Zecca L. and Hong J. S. (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 5769.
  • Bohnen N. I., Albin R. L., Koeppe R. A., Wernette K. A., Kilbourn M. R., Minoshima S. and Frey K. A. (2006) Positron emission tomography of monoaminergic vesicular binding in aging and parkinson disease. J. Cereb. Blood Flow Metab. 26, 11981212.
  • Brooks D. J. (2003) Imaging end points for monitoring neuroprotection in parkinson’s disease. Ann. Neurol. 53 (Suppl 3), S1108;.discussion S118-119.
  • Caudle W. M., Richardson J. R., Shepherd K. R. et al. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 81388148.
  • Chen M. K. and Guilarte T. R. (2006) Imaging the peripheral benzodiazepine receptor response in central nervous system demyelination and remyelination. Toxicol. Sci. 91, 532539.
  • Chen C. X., Huang S. Y., Zhang L. and Liu Y. J. (2005) Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells. Neurobiol. Dis. 19, 419426.
  • Dauer W. and Przedborski S. (2003) Parkinson’s disease: Mechanisms and models. Neuron 39, 889909.
  • Dean E. D., Torres G. E. and Miller G. W. (2007) Alpha-synuclein interacts with VMAT2 to regulate VMAT2 activity. Toxicol. Sci. 96(1S), 45.
  • Doudet D. J., Rosa-Neto P., Munk O. L., Ruth T. J., Jivan S. and Cumming P. (2006) Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study. Neuroimage 30, 2635.
  • Ehrin E., Farde L., De Paulis T. et al. (1985) Preparation of 11C-labelled raclopride, a new potent dopamine receptor antagonist: Preliminary PET studies of cerebral dopamine receptors in the monkey. Int. J. Appl. Radiat. Isot. 36, 269273.
  • Fleckenstein A. E. and Hanson G. R. (2003) Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol. 479, 283289.
  • Fumagalli F., Gainetdinov R. R., Wang Y. M., Valenzano K. J., Miller G. W. and Caron M. G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19, 24242431.
  • Gainetdinov R. R., Fumagalli F., Wang Y. M., Jones S. R., Levey A. I., Miller G.W and Caron M. G. (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 knock-out mice. J. Neurochem. 70, 19731978.
  • Gerhard A., Pavese N., Hotton G. et al. (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic parkinson’s disease. Neurobiol. Dis. 21, 404412.
  • Guilarte T. R., Chen M. K., McGlothan J. L. et al. (2006) Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp. Neurol. 202, 381390.
  • Hurley S. D., O’Banion M. K., Song D. D., Arana F. S., Olschowka J. A. and Haber S. N. (2003) Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp. Neurol. 184, 659668.
  • Jewett D. M., Kilbourn M. R. and Lee L. C. (1997) A simple synthesis of [11C]-dihydrotetrabenazine (DTBZ). Nucl. Med. Biol. 24, 197199.
  • Kanner B. I. and Schuldiner S. (1987) Mechanism of transport and storage of neurotransmitters. CRC Crit. Rev. Biochem. 22, 138.
  • Kropholler M. A, Boellaard R., Schuitemaker A., Van Berckel B. N., Luurtsema G., Windhorst A. D. and Lammertsma A. A. (2005) Development of a tracer kinetic plasma input model for (R)-[11C]-PK11195 brain studies. J. Cereb. Blood Flow Metab. 25, 842851.
  • Kuusisto E., Parkkinen L. and Alafuzoff I. (2003) Morphogenesis of lewy bodies: Dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 12411253.
  • Kuwabara H., Lee J. S. and Wong D. F. (2004) Measurements of dopamine D2 receptor density with bolus-plus-infusion transformation of bolus-injection [11C]raclopride PET. NeuroImage 22, 117118.
  • Lammerstma A. A. and Hume S. P. (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153158.
  • Langston J. W. (2006) The parkinson’s complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591596.
  • Lee C. S., Samii A., Sossi V. et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in parkinson’s disease. Ann. Neurol. 47, 493503.
  • Lee H. J., Shin S. Y., Choi C., Lee Y. H. and Lee S. J. (2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277, 54115417.
  • Liberatore G. T., Jackson-Lewis V., Vukosavic S. et al. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of parkinson disease. Nat. Med. 5, 14031409.
  • Logan J., Fowler J. S., Volkow N. D., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M. and Przedborski S. (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 10, 740747.
  • Lotharius J. and Brundin P. (2002) Pathogenesis of parkinson’s disease: Dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932942.
  • Maes F., Collignon A., Vandermeulen D., Marchal G. and Suetens P. (1997) Multimodality image registration by maximization of mutual information. IEEE Trans. Med. Imaging 16, 187198.
  • Miller G. W., Gainetdinov R. R., Levey A. I. and Caron M. G. (1999) Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20, 424429.
  • Mori F., Nishie M., Kakita A., Yoshimoto M., Takahashi H. and Wakabayashi K. (2006) Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in parkinson disease substantia nigra. J. Neuropathol. Exp. Neurol. 65, 808815.
  • Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T. and Torizuka T. (2005) Microglial activation and dopamine terminal loss in early parkinson’s disease. Ann. Neurol. 57, 168175.
  • Papadopoulos V., Baraldi M., Guilarte T. R. et al. (2006) Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402409.
  • Pavese N., Gerhard A., Tai Y. F. et al. (2006) Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology 66, 16381643.
  • Pirker W., Djamshidian S., Asenbaum S., Gerschlager W., Tribl G., Hoffmann M. and Brucke T. (2002) Progression of dopaminergic degeneration in parkinson’s disease and atypical parkinsonism: A longitudinal beta-CIT SPECT study. Mov. Disord. 17, 4553.
  • Ravina B., Eidelberg D., Ahlskog J. E. et al. (2005) The role of radiotracer imaging in Parkinson’s disease. Neurology 64, 208215.
  • Sidhu A., Wersinger C. and Vernier P. (2004) Alpha-synuclein regulation of the dopaminergic transporter: A possible role in the pathogenesis of parkinson’s disease. FEBS Lett. 565, 15.
  • Takahashi N., Miner L. L., Sora I., Ujike H., Revay R. S., Kostic V., Jackson-Lewis V., Przedborski S. and Uhl G. R. (1997) VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA 94, 99389943.
  • Volles M. J. and Lansbury Jr P. T. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595602.
  • Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C. and Lansbury Jr P. T. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of parkinson’s disease. Biochemistry 40, 78127819.
  • Wong D. F., Yung B., Dannals R. F. et al. (1993) In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]-WIN 35,428. Synapse 15, 130142.
  • Wu Y. and Carson R. E. (2002) Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J. Cereb. Blood Flow Metab. 22, 14401452.
  • Yamamoto S., Fukae J., Mori H., Mizuno Y. and Hattori N. (2006) Positive immunoreactivity for vesicular monoamine transporter 2 in lewy bodies and lewy neurites in substantia nigra. Neurosci. Lett. 396, 187191.
  • Zhou Y., Chen M. K., Endres C. J., Ye W., Brasic J. R., Alexander M., Crabb A. H., Guilarte T. R. and Wong D. F. (2006) An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. Neuroimage 33, 550563.